AI Won't Save Medtech From Pharma — It Might Make the Gap Worse

Article 3 of 5 in the Pharma vs. Medtech Series

Pharma and Medtech both chase AI and both get called healthcare, but almost nobody asks if AI helps them equally — it doesn't, and the reasons hold up dimension by dimension.

Prepared by Richstorm.co

Key Takeaways

• Pharma's net margin runs nearly three times medtech's (16.09% vs. 5.80%, same source, same period), and AI reinforces the exact mechanism behind that gap.

• Every molecule AI helps discover still gets the same patent and FDA exclusivity a human-discovered molecule would — AI changes speed, not the protection itself.

• Medtech has almost no equivalent mechanism for AI to reinforce, except cardiovascular devices and surgical robotics — and even there, AI's effect is a split verdict.

• AI's biggest pharma gains are front-loaded in early discovery — Phase I success rates jump, but Phase II converges to the same ~40% as traditional drugs, so the advantage doesn't fully reach the finish line yet.

• A flat ~40% Phase II success rate combined with more total AI-generated candidates likely means more approved, competing drugs overall — real supply growth.

AI's Impact, Dimension by Dimension

AI is often described as a rising tide that will lift all of healthcare. But industries don't benefit from new technologies equally. Whether AI creates lasting value depends on the economic mechanism it reinforces. The comparison below examines how AI affects the key drivers of competitive advantage in pharma and medtech—and why the same technology produces very different economic outcomes.

Legal Protection vs. Switching Costs

Pharma and Medtech protect competitive advantage in fundamentally different ways. Pharma relies on legal exclusivity that prevents competitors from selling the same product, while medtech—where durable moats exist at all—relies primarily on customer switching costs that discourage adoption of competing products.

Conclusion

AI reinforces pharma's competitive advantage because it accelerates the one activity already protected by patents and FDA exclusivity: discovering new molecules. Every AI-discovered drug still receives the same legal protection as one discovered through traditional research. Medtech is fundamentally different. Outside a handful of categories such as surgical robotics and cardiovascular devices, AI improves product features rather than the economic mechanism that creates durable competitive advantage.

AI may ultimately reshape both industries, but it is unlikely to narrow the structural gap between them. If anything, it strengthens the mechanism that already favors pharma while leaving most of medtech's competitive dynamics largely unchanged.

Read the full breakdown here: The Medtech Moat Map: Where the Advantage Is Real

Article 4 of 5 in the Pharma vs. Medtech Series